Resistance of Different Tumor Cells to Lysis by Lymphokine Activated Killer Cells Can Be Mediated by Distinct Mechanisms

This publication has 13 references indexed in Scilit:

• T cell target 1 (TCT.1): a novel target molecule for human non-major histocompatibility complex-restricted T lymphocytes.
  The Journal of Experimental Medicine, 1990
• The potential usefulness of interleukin-2 activated bone marrow cells as an active therapeutic tool against cytomegalovirus infection in a bone marrow transplantation setting
  Journal of Clinical Immunology, 1989
• The role of oxidant injury in tumor cell sensitivity to recombinant human tumor necrosis factor in vivo. Implications for mechanisms of action.
  The Journal of Immunology, 1989
• The expression and functional involvement of laminin-like molecules in non-MHC restricted cytotoxicity by human Leu-19+/CD3- natural killer lymphocytes.
  The Journal of Immunology, 1988
• Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
  The Journal of Immunology, 1988
• Self-Induction of Defense Against Tumor Necrosis Factor Cytotoxicity in Tumor Cells and Normal Cells
  Immunopharmacology and Immunotoxicology, 1988
• Human T cell clones use a CD3-associated surface antigen recognition structure to exhibit both NK-like and allogeneic cytotoxic reactivity.
  The Journal of Immunology, 1987
• Cytolytic and biochemical properties of cytoplasmic granules of murine lymphokine-activated killer cells.
  The Journal of Immunology, 1986
• Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.
  The Journal of Experimental Medicine, 1984
• Rabbit tumor necrosis factor: mechanism of action
  Infection and Immunity, 1981